
Alaunos Therapeutics
(NASDAQ) TCRT
Alaunos Therapeutics Financials at a Glance
Market Cap
$5.91M
Revenue (TTM)
$3.00K
Net Income (TTM)
$4.11M
EPS (TTM)
$-2.17
P/E Ratio
-1.13
Dividend
$0.00
Beta (Volatility)
1.43 (Average)
Dividend
$0.00
Beta (Volatility)
1.43 (Average)
Price
$2.58
Volume
0
Open
$2.46
Price
$2.58
Volume
0
Open
$2.46
Previous Close
$2.58
Daily Range
$2.46 - $2.63
52-Week Range
$1.67 - $6.20
Dividend
$0.00
Beta (Volatility)
1.43 (Average)
Price
$2.58
Volume
0
Open
$2.46
Previous Close
$2.58
Daily Range
$2.46 - $2.63
52-Week Range
$1.67 - $6.20
TCRT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Alaunos Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
1
CEO
Holger Weis, CPA
Website
www.alaunos.comHeadquarters
Houston, TX 77054, US
TCRT Financials
Key Financial Metrics (TTM)
Gross Margin
-63%
Operating Margin
-1382%
Net Income Margin
-1370%
Return on Equity
-350%
Return on Capital
-3%
Return on Assets
-2%
Earnings Yield
-88.50%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.91M
Shares Outstanding
2.40M
Volume
0
Avg. Volume
15.45K
Financials (TTM)
Gross Profit
$5.00K
Operating Income
$4.22M
EBITDA
$4.22M
Operating Cash Flow
$2.87M
Capital Expenditure
$98.00K
Free Cash Flow
$2.97M
Cash & ST Invst.
$1.39M
Total Debt
$0.00
Alaunos Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$8.00K
-500.0%
Gross Margin
0.00%
N/A
Market Cap
$5.91M
N/A
Market Cap/Employee
$5.91M
N/A
Employees
1
N/A
Net Income
$1.01M
+6.2%
EBITDA
$1.01M
+5.7%
Quarterly Fundamentals
Net Cash
$354.00K
+11.0%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-2.18%
N/A
Return on Invested Capital
-3.22%
N/A
Free Cash Flow
$1.03M
-33.5%
Operating Cash Flow
$1.03M
-33.5%







